RemeGen has submitted a Biologics License Application (BLA) to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China for IgAN, which if approved would ...

Final results were announced from the phase 3 APPLAUSE-IgAN trial evaluating iptacopan in patients with IgA nephropathy.

Late-breaking results of ORIGIN Phase 2b trial supporting further evaluation of atacicept 150 mg as a potential disease-modifying treatment for IgAN will be presented at 60th European Renal ...

KDIGO's new IgA nephropathy guideline shifts the treatment paradigm from supportive care alone to targeting the disease's immunologic nature.

Vera Therapeutics Inc. (NASDAQ:VERA) is one of the best high short interest stocks with huge upside potential. Earlier in June, Vera Therapeutics announced positive topline results from its ongoing ...

Atrasentan demonstrated mean proteinuria reductions of 38.1% proteinuria at six weeks of treatment, 48.3% at 12 weeks of treatment and 54.7% at 24 weeks of treatment There were no meaningful changes ...

ST. GALLEN, Switzerland, and SAN DIEGO, Sept. 26, 2025 /PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) support the recent publication of the updated clinical practice ...

On Wednesday, Vor Bio Inc. (NASDAQ:VOR) announced that its collaborator, RemeGen Co., Ltd., achieved the primary endpoint in Stage A of a Phase 3 clinical study in China evaluating telitacicept in ...

First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025 UK Clinical Trial Application (CTA) approval shortly follows U.S. IND clearance and granting of European Medicine Agency ...